Clinical Trial Enrolling Patients with Diabetic Gastroparesis
Tranzyme is currently in the process of enrolling patients with gastroparesis due to Type 1 and Type 2 Diabetes Mellitus for its Phase 2 study of once daily, orally administered TZP-102. See link below which provides additional details about the study and enrollment criteria. http://clinicaltrials.gov/ct2/show/NCT00889486
